Safety of nontumor necrosis factor-targeted biologics in the COVID-19 pandemic.
作者信息
Akiyama Shintaro, Yamada Akihiro, Sakuraba Atsushi
机构信息
Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
Department of Internal Medicine, Section of Gastroenterology, Toho University Sakura Medical Center, Chiba, Japan.
出版信息
J Med Virol. 2021 Feb;93(2):714-716. doi: 10.1002/jmv.26528. Epub 2020 Oct 5.
Abstract
摘要
相似文献
1
Safety of nontumor necrosis factor-targeted biologics in the COVID-19 pandemic.
J Med Virol. 2021 Feb;93(2):714-716. doi: 10.1002/jmv.26528. Epub 2020 Oct 5.
2
Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment.
JAMA. 2022 Jun 21;327(23):2281. doi: 10.1001/jama.2022.9846.
3
Repigmentation of vitiligo with oral baricitinib.
Australas J Dermatol. 2020 Nov;61(4):374-376. doi: 10.1111/ajd.13348. Epub 2020 Jun 3.
4
Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.
Ann Rheum Dis. 2021 Sep;80(9):1245-1246. doi: 10.1136/annrheumdis-2021-220049. Epub 2021 Jun 7.
5
Audio Interview: Covid-19 Vaccine Fundamentals.
N Engl J Med. 2020 Dec 17;383(25):e146. doi: 10.1056/NEJMe2035370.
6
Advances in clinical outcomes: What we have learned during the COVID-19 pandemic.
J Allergy Clin Immunol. 2022 Feb;149(2):569-578. doi: 10.1016/j.jaci.2021.12.775. Epub 2021 Dec 24.
7
Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome.
Clin Exp Dermatol. 2021 Oct;46(7):1330-1332. doi: 10.1111/ced.14712. Epub 2021 Jun 4.
8
Baricitinib in Alopecia Areata.
N Engl J Med. 2022 May 5;386(18):1751-1752. doi: 10.1056/NEJMe2203440.
9
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.
Leukemia. 2021 Sep;35(9):2616-2620. doi: 10.1038/s41375-021-01266-6. Epub 2021 May 14.
10
Oral Baricitinib Restores Hair Loss in Alopecia Areata.
JAMA. 2022 Jun 28;327(24):2386. doi: 10.1001/jama.2022.10378.
本文引用的文献
1
Preventing COVID-19-induced pneumonia with anticytokine therapy.
Lancet Rheumatol. 2020 May;2(5):e255-e256. doi: 10.1016/S2665-9913(20)30092-8. Epub 2020 Apr 6.
2
Thoughts on COVID-19 and autoimmune diseases.
Lupus Sci Med. 2020 Apr 3;7(1):e000396. doi: 10.1136/lupus-2020-000396. eCollection 2020.
3
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact.
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.04.017. Epub 2020 Apr 23.
4
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.
J Infect. 2020 Jun;80(6):607-613. doi: 10.1016/j.jinf.2020.03.037. Epub 2020 Apr 10.
5
Trend and forecasting of the COVID-19 outbreak in China.
J Infect. 2020 Apr;80(4):469-496. doi: 10.1016/j.jinf.2020.02.014. Epub 2020 Feb 27.
6
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
7
Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Clin Gastroenterol Hepatol. 2020 Jan;18(1):69-81.e3. doi: 10.1016/j.cgh.2019.02.044. Epub 2019 Mar 12.
8
Review of IL-17 inhibitors for psoriasis.
J Dermatolog Treat. 2018 Jun;29(4):347-352. doi: 10.1080/09546634.2017.1395796. Epub 2017 Nov 10.
9
The safety of ustekinumab for the treatment of psoriatic arthritis.
Expert Opin Drug Saf. 2017 Jun;16(6):733-742. doi: 10.1080/14740338.2017.1323864. Epub 2017 May 9.
10
Janus kinase inhibitors in dermatology: A systematic review.
J Am Acad Dermatol. 2017 Apr;76(4):745-753.e19. doi: 10.1016/j.jaad.2016.12.004. Epub 2017 Feb 4.
Zotero 插件